This study investigated the efficacy and safety of toripalimab in combination with concurrent platinum‐based chemoradiation in patients with untreated locally advanced cervical cancer. Eligible patients received toripalimab 240 mg once every 3 weeks in combination with concurrent platinum‐based chemoradiotherapy, followed by the maintenance of toripalimab once every 6 weeks up to 1 year. The primary endpoint was objective response rate (ORR). Secondary endpoints included 2‐year and 3‐year progression‐free survival (PFS) rates, 3‐year overall survival (OS) rate, and safety. Biomarker analysis of PD‐L1 expression and genomic mutational analysis by next‐generation sequencing were conducted, as well as PD‐L1 expression on tumor biopsies. A total of 82 patients were enrolled. The median follow‐up was 21 months (range, 5.2–44.5 months). The ORR and disease control rate were both 87.8% among the 82 patients. Median PFS and OS were not reached. A trend toward longer PFS was observed in the populations with a PD‐L1 combined positive score ≥10, low tumor mutation burden and loss of heterozygosity in human leukocyte antigen (HLA LOH) detected populations. A total of 37 patients experienced treatment‐related adverse events, of which 17 (20.7%) patients experienced grade 3 or higher adverse events. Collectively, toripalimab plus concurrent platinum‐based chemoradiotherapy showed promising antitumor efficacy with acceptable safety profiles in patients with untreated locally advanced cervical cancer.
Brachytherapy-integrated hyperthermia combines implant-based radiation delivery with localized heating, but the evidence spans heterogeneous diseases, devices, temperature measurements, and study designs. We conducted a systematic search-based evidence map with revision-stage record reconciliation, human adjudication, report-to-study linkage, and design-matched clinical appraisal. Of 8189 unique records screened in the original search, 2178 candidate or uncertain records underwent documented revision-stage human adjudication. During acceptance-stage revision, all 3919 records originally assigned to the machine exclusion stratum also received a primary human title/abstract re-screen decision; 3916 exclusions were confirmed and three boundary records were reclassified. The final unified worklist comprised 285 records. Ninety-two verified/supporting report units were adjudicated (15 direct clinical, 34 technical/platform, 24 supporting, and 19 excluded). The 15 core clinical reports represented 14 independent studies and generated 17 appraisal records using RoB 2, ROBINS-I, and JBI tools. Two randomised phase III trials did not show improved disease control or survival with added hyperthermia; both were judged to raise some concerns for risk of bias, and both had important thermal intervention limitations. One non-randomised cervical comparison was at serious risk of bias from confounding by indication. Uncontrolled prostate, anal, gynaecologic, and mixed pelvic series supported procedural feasibility but not causal efficacy. Two predefined supplemental saturation batches added no new eligible evidence in any family or domain. The evidence supports standardised multipoint thermometry, measurement-anchored spatial reconstruction, coupled planning, platform qualification, and disease-specific trials only after thermal fidelity gates are passed.